PuSH - Publikationsserver des Helmholtz Zentrums München

Kobold, S.

An in sitro assay to predict primary resistance to PD-1 blockade.

Trends Mol. Med. 27, 297-298 (2021)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Immune check point inhibition (ICI) is a paradigm shift in oncology, but most patients treated with ICI will not respond to treatment. Thus, the need for predictive biomarkers for ICI is high. Dubuisson and colleagues have now reported on a new functional assay that might accurately inform on ICI response.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Cancer Immunology ; Immune Check Point Inhibition ; Immuno-oncology ; In Sitro
ISSN (print) / ISBN 1471-4914
e-ISSN 1471-499X
Zeitschrift Trends in Molecular Medicine
Quellenangaben Band: 27, Heft: 4, Seiten: 297-298 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort The Boulevard, Langford Lane, Kidlington, Oxford Ox5 1gb, Oxon, England
Begutachtungsstatus Peer reviewed
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
Förderungen Melanoma Research Alliance
Hector foundation
International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
German Cancer Aid
ErnstJung-Stiftung
LMU Munich's Institutional Strategy LMUexcellent
Bundesministerium fur Bildung und Forschung Project Onkattract
European Research Council
German Research Foundation
Deutsche Jose-Carreras Leukamie-Stiftung
Marie-SklodowskaCurie ProgramTraining Network for the Immunotherapy of Cancer - H2020 Program of the European Union